Crohn's Disease

What it is

Crohn's disease is a chronic inflammatory bowel disease that causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, weight loss, fatigue, and malnutrition. The inflammation can occur anywhere from the mouth to the anus, often in patchy distributions. Severity varies widely; some patients experience prolonged remissions on biologic therapy, while others require multiple surgeries.

Cannabis and cannabis-derived therapies

The 2017 NASEM consensus report classified cannabis evidence for inflammatory bowel disease, including Crohn's, as limited. Several small clinical trials have reported improvements in patient-reported quality of life, pain, and appetite, but did not demonstrate cannabis or cannabinoids as effective for inducing or maintaining clinical remission as measured by endoscopic or biomarker outcomes.

Most US medical cannabis programs list Crohn's disease as a qualifying condition. Patients should not substitute cannabis for evidence-based IBD therapies (biologics, immunomodulators, corticosteroids) and should coordinate use with their gastroenterologist.

Clinical-trial evidence

Several randomized trials have evaluated cannabis or cannabinoids in Crohn's disease. Key findings:

• Naftali et al., 2013 (Clinical Gastroenterology and Hepatology): 21-patient placebo-controlled trial of smoked cannabis in moderate-severe Crohn's. Clinical response (CDAI reduction ≥100 points) in 90% cannabis vs 40% placebo. No significant change in CRP or inflammatory biomarkers. Small sample size limits generalization.
• Naftali et al., 2017 (Digestive Diseases and Sciences): CBD-only trial showed no clinical benefit, suggesting THC may be the active component for symptomatic response.
• Naftali et al., 2021: 8-week trial of smoked cannabis with crossover; significant improvement in patient-reported quality of life and pain scores; no significant change in inflammatory markers or mucosal healing.
• Cochrane reviews 2018 and 2024: consistent finding that cannabis improves patient-reported symptoms but does not induce or maintain endoscopic remission.

The pattern across trials is clear: cannabis can improve symptomatic experience of Crohn's disease without changing the underlying inflammatory process. This is a meaningful but limited benefit.

Endocannabinoid system and intestinal inflammation

The endocannabinoid system is densely active throughout the gastrointestinal tract. CB1 receptors are expressed on enteric neurons and modulate gut motility, secretion, and visceral pain. CB2 receptors are concentrated on intestinal immune cells and modulate inflammatory responses.

Preclinical models of colitis show that CB1 and CB2 activation can reduce intestinal inflammation. Translation to human disease has been incomplete; the receptor distribution is preserved but the pharmacological response to exogenous cannabinoids has not consistently reduced clinical inflammation in Crohn's patients.

Standard Crohn's therapy

Cannabis is adjunctive to evidence-based Crohn's therapy:

• 5-aminosalicylates (mesalamine, sulfasalazine): primarily for ulcerative colitis; limited role in Crohn's.
• Corticosteroids (prednisone, budesonide): induce remission; not for maintenance due to adverse effects.
• Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate): maintenance therapy.
• Anti-TNF biologics (infliximab, adalimumab, certolizumab pegol): induction and maintenance.
• Anti-integrin (vedolizumab): gut-selective biologic.
• Anti-interleukin (ustekinumab, risankizumab): newer biologic options.
• JAK inhibitors (upadacitinib): small-molecule oral therapy.
• Surgery: for stricturing, fistulizing, or refractory disease.

Cannabis does not replace any of these. Substituting cannabis for biologic therapy is associated with flare risk and disease-progression risk.

Drug interactions with Crohn's therapies

• Methotrexate: no major cannabis interaction documented, but additive hepatotoxicity is possible with chronic high-dose cannabis.
• Azathioprine, 6-MP: CBD inhibits CYP enzymes that affect azathioprine metabolism; clinical significance unclear.
• TNF inhibitors: cannabis-related immune-modulation effects are theoretically relevant but clinical interactions are not well documented.
• JAK inhibitors (upadacitinib): CYP3A4 substrate; CBD inhibition could affect levels.
• Corticosteroids: additive metabolic effects with chronic combined use (hyperglycemia, weight redistribution).
• Opioids (used for breakthrough Crohn's pain): additive CNS depression. Cannabis-opioid combination requires monitoring.

Smoking-specific risk in Crohn's

Cigarette smoking is a documented risk factor for worse Crohn's outcomes (increased relapse rate, more aggressive disease course, higher surgery rate). The mechanism is not fully understood but appears to involve nicotine and combustion products.

By analogy and by some direct evidence, cannabis smoking carries similar risk. Crohn's patients who use cannabis should generally prefer:

• Vaporization: avoids most combustion products.
• Oral preparations: oils, capsules, edibles, tinctures.
• Sublingual: avoids first-pass metabolism for predictable dosing.

Ulcerative colitis shows an opposite smoking-disease relationship (smoking is associated with milder UC course); cannabis effects in UC may differ from Crohn's.

Cannabis hyperemesis syndrome

Cannabis hyperemesis syndrome (CHS) is a paradoxical cyclic vomiting condition seen in heavy chronic cannabis users. It presents as recurrent severe nausea, vomiting, and abdominal pain — sometimes mimicking Crohn's flare. CHS is relieved by hot showers (a characteristic feature) and resolves with cannabis cessation. Crohn's patients with heavy cannabis use should be evaluated for CHS if presenting with new-onset cyclic vomiting.

Nutritional considerations

Crohn's disease can cause malabsorption, micronutrient deficiencies, and weight loss. Cannabis-related appetite stimulation may help with caloric intake in malnourished patients but does not address underlying malabsorption. Cannabis use should be coordinated with nutritional management by the gastroenterology team.

Practical guidance

• Cannabis is adjunctive to disease-modifying Crohn's therapy, not a substitute.
• Vaporization or oral preparations preferred over smoking.
• Coordinate with gastroenterology, particularly when starting or modifying biologics.
• Monitor for cannabis hyperemesis syndrome if new cyclic vomiting develops in a chronic cannabis user.
• Disclose cannabis use to all prescribers, especially before any surgical procedure.
• Pediatric Crohn's patients should have cannabis use coordinated with both pediatric gastroenterology and the medical-cannabis program clinician.

Related conditions

The mmjnow library covers ulcerative-colitis (the other major IBD subtype) and inflammatory-bowel-disease (the parent category) as separate condition pages. Patients with Crohn's commonly have chronic-pain, anxiety-disorders, and (in active disease) cachexia and nausea co-occurrence. Cross-reference each for additional clinical detail.